Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

NCT03743428 · clinicaltrials.gov ↗

NA

Phase

SUSPENDED

Status

40

Enrollment

OTHER

Sponsor class

Stopped Too slow speed for recruiting.

Conditions

Colorectal Neoplasms

Interventions

DRUG: Apatinib Mesylate Tablets
DRUG: Bevacizumab Injection

Sponsor

Shenzhen People's Hospital